MD (Oncologist) & Researcher @hug_ge (Geneva,CH) •PhD (@Cambridge_Uni) •MPH @LSHTM
Geneva, Switzerland
Joined February 2009
- Tweets3K
- Following817
- Followers774
- Likes6.6K
Pinned Tweet
We were awarded the Ferenc Bojan Young Investigator Award at the @EPHconference. Happy that our work got recognised and the Bus Santé is continuing to produce relevant public health research.
@iguessous @Hopitaux_unige @unige_en @UNIGEnews
Ocafu's Tortilla, as suggested by @JavierCortesMD. Thanks for the great gourmet suggestion and mentorship over these last 3 days.
José Sandoval retweeted
#ESMO25
So nice to see my friend and colleague @JLSandoval co-chairing with Carolien Schröder a session focusing on tailoring breast cancer care for special populations.👍👏 @DOncologie @hug_ge
José Sandoval retweeted
Congratulations @JLSandoval et al. for this study exploring biomarkers in ovarian cancer!
Very nice collaborative effort, well done 👍 👏#ASCO25
@hug_ge @institut_curie !
Interesting data from PADA-1 trial at #esmobreast25 by FC Bidard @institut_curie
Rate of ESR1m detection changes over time suggesting selection of a subclone rather than ESR1m emergence, factors associated with ESR1m detection were identified. Same for ESR1m detection w/o PD.
José Sandoval retweeted
Which companies are driving the future of #BreastCancer treatment? @Larvol CLIN highlights the innovators who stood out at @SABCSSanAntonio 2024.
Discover more: t.ly/24Mrr
#LARVOL #SABCS24 #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates
José Sandoval retweeted
Discover key discussions and reactions on top trials from @SABCSSanAntonio 2024 with @Larvol CLIN.
Learn More: t.ly/24Mrr
#LARVOL #SABCS24 #Oncology #CancerResearch #BreastCancer #CancerData #CancerCare #OncologyUpdates
José Sandoval retweeted
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @OncoAlert
José Sandoval retweeted
📡SOLTI-2103 VALENTINE Trial: Phase II Trial of Neoadjuvant Patritumab Deruxtecan vs. Chemotherapy for High-Risk HR+/HER2- Early Breast Cancer
The SOLTI-2103 VALENTINE trial at SABCS 2024 highlighted the promising potential of HER3-DXd in neoadjuvant treatment for high-risk HR+/HER2- early breast cancer, showing comparable pathological complete response rates to chemotherapy, but further follow-up is needed to assess its impact on event-free survival and quality of life.
@MOliveira_MD @_SOLTI @stolaney1 @GaiaGriguolo @SuyogCancer @puneetsinghmd @JLSandoval
Discover more about the SOLTI VALENTINE trial and its potential in breast cancer treatment:
oncodaily.com/blog/valentine…
#BreastCancer #OncoDaily #Oncology #SABCS24 #MedEd #MedX #MedNews #Medicine
CamRelief, early TNBC, NACT +/- periop Camrelizumab (#SABCS24):
- Cape allowed.
- pCR rate improved (12% delta).
- No EFS benefit yet (immature).
Looking similar to GeparDouze. Diff with KN522 a question of anti-PD-1 vs anti-PD-L1, or cape being permitted? Both? Asian patients?
GeparDouze trial in early TNBC, NACT +/- periop Atezo at #SABCS24:
- No EFS benefit
- Cape allowed from Feb 2020 (why not earlier?)
- No clear EFS differences by pCR status.
Another negative trial for Atezo. How would KN522 results have differed if Cape had been allowed? 🤔
Anthracyclines in High Genomic Risk N0 HR+/HER2- EBC in TAILORx (#SABCS24):
- RS 31 cutoff predicts 5y DRFI benefit with Anthra
-mainly in postmenopausal (OFS effect?).
- Note: ttt not randomised.
🧠 Vogl NY asks: Could Ki67 offer similar predictive insights?🙃
ZEST trial: Niraparib in patients with MRD (ctDNA+ during ctDNA surveillance) EBC (TNBC or tBRCA+) (#SABCS24):
- Only 147/1901 patients had ctDNA+, 40 randomised
- 800 to be randomised
- study terminated
Cautionary tale on the challenges of doing MRD-guided RCTs in EBC.
PATINA trial in HER2+ ER+ MBC, Trast+Pert+ET +/- Palbociclib (#SABCS24):
- PFS benefit: 44 vs 29 months👏
- No clear OS benefit
- Worse toxicity profile.
DB09 data in 6 months and T-DXd likely moving to 1L. the future role of PATINA uncertain. Complex decisions ahead!🤔
Important study from EBCCTG on obesity & prognosis in EBC (#SABCS24):
- Strong link: Worse outcomes with higher BMI.
- Especially impactful in premenopausal women.
- Independent of LN and ER status.
A stark reminder of the broader consequences of the obesity epidemic. 🌍
COMET trial, active monitoring vs surgery (+/-RT) in low risk DCIS at #SABCS24 :
- 2y IBC rate non-inferior (dif: 1.7%)
- most got Adj ET
- 31% women didn't adhere to randomisation, favouring AM
But is QoL better than surgery + RT w/o ET?
jamanetwork.com/journals/jam…
Key insights for "Good Risk" DCIS patients with BCS and forgoing Adj RT at #SABCS24 :
- Adjuvant tamoxifen shows invasive IBR benefit.
- No difference in contralateral breast events noted.
Crucial data for informed discussions on de-escalating RT vs ET in DCIS management. 🤝
EUROPA trial 1st interim analysis at #SABCS24 :
ET only vs RT only for women >70 with Luminal A pT1pN0 tumors.
QoL significantly better without ET as expected
Awaiting IBTR data.
Identifying who can forgo ET remains a priority.
More trials will join EUROPA. Stay tuned! :)
José Sandoval retweeted
📌Highlights from Day 1 of SABCS 2024
SABCS 2024, taking place from December 10-13 in San Antonio, TX, is featuring expert-led lectures, case discussions, and presentations on the latest advancements in breast cancer biology, diagnosis, and treatment. With over 10,000 attendees from 102+ countries, the symposium is providing cutting-edge insights to oncologists, researchers, and healthcare professionals worldwide.
oncodaily.com/url/202361
@SABCSSanAntonio @tmprowell @DrSGraff @ElisaAgostinett @Lucarecco @jamecancerdoc @JLSandoval @stage4kelly @SusanGKomen @to_be_elizabeth @stolaney1 @OncBrothers @LRZelman @AntoniaPearson_ @TanjaSpanic @tess_omeara @GaiaGriguolo @JeffCaoMDMBA @ErikaHamilton9 @debsetu @DrHBurstein @puneetsinghmd @Icro_Meattini @ArmandOrlandi @PTarantinoMD @royaryam
#Cancer #SABCS24 #BCSM #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology
EMBER-3 in @NEJM ahead of #SABCS24 presentation :
✨ IML mono: marginal PFS edge vs Fulv; OS trends favor IML.
📊 ESR1m? IML likely better.
💡 Key insight: IML+Abema effective post-CDK4/6i (🟢Palbo 60%, 🔵Ribo 30%).
New 2L standard? 🤔For whom?
nejm.org/doi/full/10.1056/NE…
Biomarker analysis of KN522
Interesting potential predictors of increased Pembro benefit (e.g. TMB).
IMO, if confirmed, maybe could pave the way to chemotherapy intensity de-escalation in this population (~8% of total). Also interesting to study how this relates to TILs. #SABCS24
